Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOS-1002 Alone and With Pembrolizumab in Advanced Solid Tumors
NCT05763004Phase 1Completed
- Sponsor
- ImmunOs Therapeutics
- Start
- Mar 2023
- Primary completion
- May 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of IOS-1002 in solid tumor (2 arms), sponsored by ImmunOs Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 48 months. Started Mar 2023; status: completed.
02
Drugs
IOS-1002
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05763004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05763004.